Evaluation of the dual peroxisome proliferator–activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial
Lincoff, A. Michael, MD, Tardif, Jean-Claude, MD, Neal, Bruce, PhD, Nicholls, Stephen J., MBBS, PhD, Rydén, Lars, MD, Schwartz, Gregory G., MD, PhD, Malmberg, Klas, MD, Buse, John B., MD, PhD, Henry, Robert R., MD, Wedel, Hans, PhD, Weichert, Arlette, MD, Cannata, Ruth, RN, Grobbee, Diederick E., MD, PhD
Published in The American heart journal (01.09.2013)
Published in The American heart journal (01.09.2013)
Get full text
Journal Article